iiinova — where your digital self keeps evolving

Matthew Oser @matthewoser.bsky.social · 20/09/2025

Congrats Trudy. Really beautiful work!!

Reposted by Matthew Oser

Trudy G. Oliver @tgoliver.bsky.social · 17/09/2025

Super pleased to announce our latest suggesting the cell of origin for #SCLC is most likely the basal cell @nature.com, not the accepted neuroendocrine cell. Implications for the earliest events in cancer, & providing new models of tuft-like cancer. rdcu.be/eGUtj

rdcu.be

Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer

Nature - Basal cells, rather than neuroendocrine cells, have been identified as the probable origin of small cell lung cancer and other neuroendocrine–tuft cancers, explaining...

54712

Matthew Oser @matthewoser.bsky.social · 21/08/2025

This study was led by my highly talented postdoctoral fellow Shilpa Singh and was an outstanding collaboration with Circle Pharma and Deepak Nijhawan's lab at UTSW. @danafarbernews.bsky.social.

020

Matthew Oser @matthewoser.bsky.social · 21/08/2025

Thrilled to share our new work published in Nature (rdcu.be/eBCM0). We report an exciting new potential therapeutic strategy with a fascinating mechanism of action for cancers with a compromised G1–S cell cycle checkpoint, including SCLC.

rdcu.be

Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

Nature - Dual cyclin A/B RxL inhibitors selectively kill small cell lung cancer cells and other cancer cells with high E2F activity.

181